Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

143.72 -1.09 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
News headline image
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market... 
Via Benzinga
News headline image
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth ↗
Gilead Sciences (NASDAQ:GILD) CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment... 
Via MarketBeat
News headline image
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode ↗
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has... 
Via MarketBeat
News headline image
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec... 
Via StockStory
Topics Stocks
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors ↗
Via Chartmill
What's going on in today's after hours session: S&P500 movers ↗
Via Chartmill
News headline image
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? ↗
Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies. 
Via The Motley Fool
News headline image
Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗
Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
FDA Approves Gilead's New Single Tablet HIV Regimen ↗
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologically suppressed adults treating HIV. 
Via Benzinga
News headline image
3 Unpopular Stocks with Open Questions
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals? ↗
VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns. 
Via The Motley Fool
Topics ETFs
News headline image
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting ↗
Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV PrEP medicines. 
Via The Motley Fool
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
These healthcare leaders are unlikely to suspend their dividend programs. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unprofitable Stocks with Questionable Fundamentals
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
News headline image
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today ↗
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market... 
Via Benzinga
News headline image
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗
VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year. 
Via The Motley Fool
Topics ETFs
News headline image
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗
PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost. 
Via The Motley Fool
Topics ETFs
News headline image
Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022 ↗
These stocks can be safe-haven investments to hide out in amid market turmoil. 
Via The Motley Fool
Topics Economy Stocks
News headline image
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗
One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited. ↗
The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs. 
Via The Motley Fool
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?
Over the last six months, Gilead Sciences’s shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500’s 13.1% gain.... 
Via StockStory
Topics Stocks
Global Drugmakers Earmark Billions to Ramp Up Their US Footprint
Via Investor Brand Network
Topics World Trade
News headline image
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript ↗
Enrollment completed six months early; $1.5B cash runway into 2029. 
Via The Motley Fool
Topics Earnings
News headline image
KLA, Snowflake, Airbnb And A Health Care Stock On CNBC’s ‘Final Trades’ ↗
Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gilead Sciences. Joseph Terranova went for Airbnb. 
Via Benzinga
News headline image
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annualized basis producing an average annual return of 11.31%. Currently, Gilead Sciences has a market... 
Via Benzinga
News headline image
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment,... 
Via StockStory
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
78 79 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.